Clinical Utility of Central and Peripheral Airway Nitric Oxide in Aging Patients with Stable and Acute Exacerbated Chronic Obstructive Pulmonary Disease
Xiaodong Fan, Nian Zhao, Zhen Yu, Haoda Yu, Bo Yin, Lifei Zou, Yinying Zhao, Xiu-fen Qian, Xiaoyan Sai, Chu Qin, Congli Fu, Caixia Hu, Tingting Di, Yue Yang, Yan Wu, Tao Bian
Abstract
Purpose: Exhaled nitric oxide has been used as a marker of airway inflammation. The NO concentration in the central and peripheral airway/alveolar can be measured by a slow and fast exhalation flow rate to evaluate inflammation in different divisions within the respiratory tract. We hypothesized that FeNO 200 (exhaled NO at a flow rate of 200mL/s) could be used as an evaluation tool for peripheral airway/alveolar inflammation and corticosteroid therapy in chronic obstructive pulmonary disease (COPD) patients. Methods: We recruited 171 subjects into the study: 73 healthy controls, 59 stable COPD patients, and 39 acute exacerbations of COPD (AECOPD) patients. Exhaled nitric oxide (FeNO 50 (exhaled NO at a flow rate of 50mL/s)), FeNO 200 and CaNO (peripheral concentration of NO/alveolar NO) and clinical variables including pulmonary function, COPD Assessment Test (CAT), C-reactive protein concentration (CRP) and circulating eosinophil count were measured among the recruited participants. FeNO 50, FeNO 200 and CaNO were repeatedly evaluated in 39 AECOPD patients after corticosteroid treatment. Results: FeNO 200 was significantly higher in stable COPD and AECOPD patients than in healthy controls. Nevertheless, CaNO could not differentiate COPD from healthy controls. No correlation was found between circulating eosinophil counts or FEV1 and exhaled nitric oxide (FeNO 50, FeNO 200 , CaNO) in COPD patients. For AECOPD patients, 64% of patients had eosinophil counts > 100 cells/μL; 59% of patients had FeNO 200 > 10 ppb; only 31% of patients had FeNO 50 > 25 ppb. Among AECOPD patients, the high FeNO 50 and FeNO 200 groups’ levels were significantly lower than their baseline levels, and significant improvements in CAT were seen in the two groups after corticosteroid treatment. These implied a good corticosteroid response in AECOPD patients with FeNO 200 > 10ppb. Conclusion: FeNO 200 is a straightforward and feasible method to evaluate the peripheral NO concentration in COPD. FeNO200 can be a type 2 inflammation biomarker and a useful tool for predicting corticosteroid therapy in COPD. Keywords: exhaled nitric oxide, chronic obstruction pulmonary disease, corticosteroid, biomarker